NASDAQ:GLPG

Galapagos (GLPG) News Today

$42.20

+0.35 (+0.84%)

(As of 10:00 AM ET)

Compare

Today's Range: $41.84
▼
$42.22
50-Day Range: $36.50
▼
$44.52
52-Week Range: $36.17
▼
$58.67

Volume: 17,824 shs
Average Volume: 254,282 shs
Market Capitalization: $2.78 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $45.37

Get Galapagos News Delivered to You Automatically

GLPG Media Mentions By Week

GLPG Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

GLPG
News Sentiment
▼
0.12

0.55
▲
Average
Medical
News Sentiment

GLPG News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

GLPG Articles
This Week
▼
8

3
▲
GLPG Articles
Average Week

Source

Source	Headline
	Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress finance.yahoo.com - June 5 at 8:12 PM
	Galapagos Nv NPV (AMS:GLPG) Price Target Decreased by 7.53% to 49.94 msn.com - June 4 at 9:16 AM
	888 Reaffirms Maintains Rating for Galapagos (NASDAQ:GLPG) americanbankingnews.com - June 3 at 3:22 AM
	UBS Group Begins Coverage on Galapagos (NASDAQ:GLPG) americanbankingnews.com - June 2 at 1:42 AM
	JP Morgan Maintains Neutral Rating for Galapagos: Here's What You Need To Know markets.businessinsider.com - May 31 at 3:24 PM
	While public companies own 25% of Galapagos NV (AMS:GLPG), retail investors are its largest shareholders with 45% ownership finance.yahoo.com - May 30 at 9:43 AM
	Galapagos NV: Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis finanznachrichten.de - May 25 at 1:30 AM
	Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis finance.yahoo.com - May 23 at 4:55 PM
	Analysts Set Galapagos NV (NASDAQ:GLPG) Price Target at $45.37 americanbankingnews.com - May 23 at 4:30 AM
	Galapagos NV: Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023 finanznachrichten.de - May 22 at 8:13 PM
	Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023 finance.yahoo.com - May 22 at 8:13 PM
	Galapagos (NASDAQ:GLPG) Upgraded at StockNews.com americanbankingnews.com - May 10 at 2:36 AM
	Galapagos (AMS:GLPG) shareholders have endured a 82% loss from investing in the stock three years ago finance.yahoo.com - May 10 at 2:15 AM
	Galapagos (NASDAQ:GLPG) Given New $42.00 Price Target at Morgan Stanley americanbankingnews.com - May 9 at 7:48 AM
	Galapagos (NASDAQ:GLPG) Upgraded to "Outperform" at Raymond James americanbankingnews.com - May 9 at 2:54 AM
	Galapagos Stands Strong On Jyseleca Positive Clinical Data seekingalpha.com - May 6 at 1:59 AM
	Raymond James Upgrades Galapagos (NASDAQ:GLPG) to "Outperform" marketbeat.com - May 5 at 11:55 AM
	Galapagos (NASDAQ:GLPG) Shares Gap Down to $41.00 americanbankingnews.com - May 5 at 6:02 AM
	Galapagos announces first quarter 2023 financial results finance.yahoo.com - May 4 at 4:31 PM
	Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer finance.yahoo.com - May 2 at 5:24 PM
	Galapagos (GLPG) to Release Quarterly Earnings on Thursday americanbankingnews.com - May 2 at 1:08 AM
	Analysts Set Galapagos NV (NASDAQ:GLPG) PT at $49.17 americanbankingnews.com - April 30 at 7:54 AM
	Galapagos NV (NASDAQ:GLPG) Short Interest Down 33.9% in April marketbeat.com - April 28 at 11:22 AM
	Galapagos (GLPG) Scheduled to Post Earnings on Thursday marketbeat.com - April 27 at 1:07 AM
	Galapagos’ shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders’ meeting finance.yahoo.com - April 25 at 6:55 PM
	Galapagos NV (NASDAQ:GLPG) Given Average Rating of "Hold" by Analysts marketbeat.com - April 25 at 2:58 AM
	Galapagos NV (AMS:GLPG) Looks Inexpensive But Perhaps Not Attractive Enough finance.yahoo.com - April 19 at 7:09 AM
	Galapagos Islands Neighborhoods travel.usnews.com - April 18 at 9:07 PM
	Best Galapagos tours thetimes.co.uk - April 14 at 10:40 AM
	Getting Around Galapagos Islands travel.usnews.com - April 13 at 2:07 PM
	Galapagos NV (NASDAQ:GLPG) Receives $49.17 Consensus Target Price from Brokerages americanbankingnews.com - April 3 at 3:54 AM
	Galapagos NV (NASDAQ:GLPG) Receives Average Rating of "Hold" from Brokerages marketbeat.com - March 31 at 2:39 AM
	Galapagos publishes 2022 annual report and announces Annual Shareholders’ Meeting finance.yahoo.com - March 23 at 4:05 PM
	Galapagos NV (NASDAQ:GLPG) Given Average Recommendation of "Hold" by Analysts marketbeat.com - March 6 at 2:37 AM
	Point72 Asset Management L.P. Invests $597,000 in Galapagos NV (NASDAQ:GLPG) marketbeat.com - March 3 at 6:02 AM
	Galapagos' Blood Cancer Candidate Shows 100% Objective Response Rate In Relapsed/Refractory Patients finance.yahoo.com - February 18 at 9:17 AM
	Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL finance.yahoo.com - February 9 at 6:19 PM
	Galapagos shares down after announcing clinical-trial miss for Crohn’s disease finance.yahoo.com - February 9 at 1:19 PM
	Why Galapagos Stock Is Falling Today finance.yahoo.com - February 9 at 1:19 PM
	Galapagos NV (NASDAQ:GLPG) Receives Consensus Recommendation of "Hold" from Brokerages marketbeat.com - February 9 at 2:31 AM
	marketbeat.com - February 8 at 4:08 PM
	Galapagos NV (NASDAQ:GLPG) Given Consensus Recommendation of "Hold" by Analysts marketbeat.com - January 15 at 1:26 AM
	Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference finance.yahoo.com - January 3 at 6:59 PM
	3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023 finance.yahoo.com - December 28 at 2:06 PM
	Galapagos announces changes to Executive Committee finance.yahoo.com - December 22 at 7:41 PM
	On A Mission As Top European Player, Galapagos Looks For Acquisition Targets finance.yahoo.com - December 20 at 12:31 PM
	Short Interest in Galapagos NV (NASDAQ:GLPG) Rises By 7.3% marketbeat.com - December 17 at 8:23 AM
	Does Galapagos NV (GLPG) Have the Potential to Rally 34% as Wall Street Analysts Expect? finance.yahoo.com - December 16 at 3:24 PM
	Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care finance.yahoo.com - December 13 at 6:17 AM
	Down 5.9% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround finance.yahoo.com - December 8 at 5:32 PM

Get Galapagos News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:GLPG) was last updated on 6/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Galapagos (GLPG) News Today

GLPG Media Mentions By Week

GLPG Media Sentiment

GLPG News Coverage

Related Companies and Tools

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info